Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Cancer Therapies02:49

Cancer Therapies

9.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.3K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

370
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
370

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Meniscal Ramp Lesions According to the Type of Anterior Cruciate Ligament Tear: A Magnetic Resonance Imaging Study.

Journal of computer assisted tomography·2026
Same author

Refractory Periorbital Necrobiotic Xanthogranuloma Treated With Plasma Cell-Directed Therapy.

EJHaem·2026
Same author

Autoimmune HLA alleles and neoantigens predict myelodysplastic syndrome outcomes after allogeneic HSCT: A CIBMTR analysis.

iScience·2026
Same author

Contextualizing results of randomized trials in smoldering myeloma.

The oncologist·2025
Same author

Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials.

Nature reviews. Clinical oncology·2025
Same author

Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials.

The Lancet. Oncology·2025

Related Experiment Video

Updated: Nov 28, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Persistent challenges with treating multiple myeloma early.

Aaron M Goodman1, Myung S Kim2, Vinay Prasad3,4

  • 1Division of Blood and Marrow Transplantation, Department of Medicine, University of California, San Diego, La Jolla, CA.

Blood
|November 25, 2020
PubMed
Summary
This summary is machine-generated.

Early treatment for multiple myeloma (MM) and precursor diseases is expanding, but its benefits for survival and quality of life remain unclear. This commentary examines the evidence for these treatment shifts.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.1K

Related Experiment Videos

Last Updated: Nov 28, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.1K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Treatment strategies for multiple myeloma (MM) and its precursor diseases have evolved significantly over the last decade.
  • Diagnostic criteria have expanded to include patients previously ineligible for treatment due to lack of end-organ damage.
  • There is increasing interest in the early management of high-risk, smoldering multiple myeloma.

Purpose of the Study:

  • To critically evaluate the evidence supporting the expansion of treatment eligibility in multiple myeloma.
  • To discuss the implications of including patients without end-organ damage in treatment protocols.
  • To explore the rationale and potential impact of treating high-risk smoldering multiple myeloma earlier.

Main Methods:

  • Commentary and evidence review.
  • Analysis of current therapeutic strategies and diagnostic criteria in multiple myeloma.
  • Discussion of the potential benefits and drawbacks of early intervention.

Main Results:

  • The definition of multiple myeloma has broadened, encompassing a larger patient population.
  • Early treatment approaches are being increasingly adopted for smoldering multiple myeloma.
  • The impact of early treatment on survival and quality of life is not yet definitively established.

Conclusions:

  • The expansion of treatment for multiple myeloma presents new therapeutic opportunities but requires careful consideration of evidence.
  • Further research is needed to ascertain the long-term benefits of early intervention on patient survival and quality of life.
  • The implications of diagnostic expansion in multiple myeloma warrant ongoing investigation and clinical evaluation.